3,052 results on '"major bleeding"'
Search Results
52. Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
- Author
-
Eue‐Keun Choi, Jong‐Il Choi, Hyoung‐Seob Park, Gyo‐Seung Hwang, Boyoung Joung, Jong‐Youn Kim, Dae‐Hyeok Kim, Dong Gu Shin, and Hyung Wook Park
- Subjects
major bleeding ,non‐vitamin K antagonist oral anticoagulants ,real‐world ,registry ,stroke prevention ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background The real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population. Methods One‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries. Results Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (
- Published
- 2023
- Full Text
- View/download PDF
53. Frail patients who fall and their risk on major bleeding and intracranial haemorrhage. Outcomes from the Fall and Syncope Registry
- Author
-
LAR Zwart, T Germans, R Vogels, S Simsek, MEW Hemels, and RWMM Jansen
- Subjects
Frailty ,Cerebral small vessel disease ,Major bleeding ,Intra cranial haemorrhage ,Oral anticoagulation ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Major bleeding, and intracranial bleeding specifically, are severe complications related to the use of anticoagulation. To what extent the risk for major bleeding is elevated among frail older people is not well known because they are underrepresented in the randomized clinical trials (RCTs). This study investigates the risk for major bleeding (MB) and intra cranial haemorrhage (ICH) in frail older people who fall. Methods All patients 65 years and older visiting the Fall and Syncope Clinic, between November 2011 and January 2020, and underwent a MRI of the brain were eligible. Frailty was assessed with a Frailty Index, based on the accumulation of deficits model. Cerebral small vessel disease was described and evaluated as proposed in the position paper of Wardlaw and colleagues in 2013. Results 479 patients were included in this analysis. Mean follow-up was 7 years per patient (ranging from 1 month to 8 years and 5 months). 368 patients (77%) were frail. A total of 81 patients used oral anticoagulation (OAC). 17 extracranial MB of which 3 were traumatic and 14 gastrointestinal, and 16 ICH occurred. There was a total of 603.4 treatment years with OAC, and 8 MBs occurred among patients on OAC (bleeding rate 1.32 per 100 treatment years), of which 2 ICHs (bleeding rate 0.33 per 100 treatment years). The risk for extracranial MB was increased by the use of antiplatelet agents (APA) (adjusted OR 6.9, CI 95% 1.2–38.3), and by the use of OAC (adjusted OR 9.8, CI 95% 1.7–56.1). The risk for ICH was only heightened by white matter hyperintensities (WMH) (adjusted OR 3.8, CI 95% 1.0-13.4). The use of APA (adjusted OR 0.9, CI 95% 0.3–3.3) or OAC (adjusted OR 0.6, CI 95% 0.1–3.3) did not elevate the risk for ICH. Conclusion In contrast to common belief, frail patients on OAC with repeated falls show a comparable bleeding rate as in the large RCTs, and the use of OAC did not increase the risk for ICH. However, the number of MBs was low, and of ICHs very low, despite extensive follow-up in this registry.
- Published
- 2023
- Full Text
- View/download PDF
54. Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study
- Author
-
Benyapha Sombat, Sarisa Tongkaew, Aticha Nilwaranon, Mathirut Mungthin, Kanlaya Jongcherdchootrakul, and Teeraboon Lertwanichwattana
- Subjects
Warfarin ,Major bleeding ,Thromboembolism ,INR ,Medicine ,Biology (General) ,QH301-705.5 ,Science (General) ,Q1-390 - Abstract
Abstract Objectives Warfarin, like many other anticoagulants, has been linked to an elevated risk of bleeding proportional to the amount of anticoagulation used. Not only was the incidence of bleeding raised by the dosage, but the subtherapeutic international normalized ratio (INR) was also associated with increased thrombotic events. This retrospective cohort and multi-center study evaluated the incidence and risk factors of warfarin therapy complications in community hospitals in Thailand’s central and eastern regions from 2016 to 2021. Results Among 335 patients (683.90 person-year of follow-up), The incidence rate of warfarin complications was 4.91 events per 100 person-year. The independent factor associated with warfarin therapy complications was propranolol prescription (Adjusted RR: 2.29, 95%CI: 1.12–4.71). The secondary analysis was divided according to the outcome of the major bleeding and thromboembolic event. Major bleeding events, hypertension (Adjusted RR: 0.40, 95%CI: 0.17–0.95), amiodarone prescription (Adjusted RR: 5.11, 95%CI: 1.08–24.15), and propranolol prescription (Adjusted RR: 2.86, 95%CI: 1.19–6.83) were the independent risk factors. While in the major thrombotic event, non-steroidal anti-inflammatory drugs (NSAIDs) prescription was an independent factor (Adjusted RR: 10.65, 95%CI: 1.26–90.35).
- Published
- 2023
- Full Text
- View/download PDF
55. Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study
- Author
-
Shuyi Wu, Chengfu Guan, Wenlin Xu, Feilong Zhang, Nianxu Huang, Xia Chen, Wang Zhang, Wei Hu, Jun Su, Hengfen Dai, Ping Gu, Xiaohong Huang, Xiaoming Du, Ruijuan Li, Qiaowei Zheng, Xiangsheng Lin, Yanxia Zhang, Lang Zou, Yuxin Liu, Min Zhang, Xiumei Liu, Zhu Zhu, Jianjun Sun, Shanshan Hong, Weibin She, and Jinhua Zhang
- Subjects
Radiofrequency ablation ,Direct oral anticoagulants ,Non-valvular atrial fibrillation ,Major bleeding ,Thrombosis ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Background Based on the few available studies on the prognostic benefit of using direct oral anticoagulants (DOACs) after atrial fibrillation (AF) ablation. Therefore, this study aimed to evaluate the prognostic differences between patients who underwent radiofrequency ablation (RFA) and those without RFA taking DOACs. Methods This is a multicenter retrospective cohort study enrolling 6137 patients with non-valvular AF (NVAF) at 15 hospitals in China. Patient information was collected through a mean follow-up of 10 months and medical record queries. Clinical outcomes included major bleeding, total bleeding, thrombosis, all-cause death, and a composite endpoint of bleeding, thrombosis, and all-cause death. Results After adjusting for confounders and propensity score matching (PSM), patients with RFA of NVAF had a significantly lower risk of major bleeding [OR 0.278 (95% CI, 0.150-0.515), P
- Published
- 2023
- Full Text
- View/download PDF
56. Real-world clinical outcomes of oral anticoagulants among Japanese patients with atrial fibrillation and concomitant coronary artery disease
- Author
-
Yijiao Chen, Xiaoqian Gong, and Haikun Bao
- Subjects
Asian ,Atrial fibrillation ,Coronary artery disease ,Major bleeding ,Non-vitamin K antagonist oral anticoagulant ,Warfarin ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Stroke prevention is complicated in patients with atrial fibrillation (AF) and coronary artery disease (CAD). We compared the risk of major bleeding among Japanese patients with AF and CAD commencing warfarin, dabigatran, or rivaroxaban. Methods: This study included adults with AF and CAD who were newly prescribed the non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran or rivaroxaban, or warfarin, and registered between 18 April 2011 through 31 December 2020 in the Medical Data Vision hospital-based clinical database. The primary outcome was major bleeding, and the secondary outcome was a composite of stroke, systemic embolism, myocardial infarction, all-cause inpatient mortality, major bleeding, major gastrointestinal bleeding, and intracerebral hemorrhage. Cox proportional hazard models with stabilized inverse probability treatment weighting were used to estimate hazard ratios (HRs) with 95 % CIs via a two-step approach; first between warfarin and each NOAC, then between NOACs if sample size conditions were met. Results: Dabigatran, rivaroxaban, and warfarin groups included 6712, 20,329, and 12,316 patients, respectively. Major bleeding risk was lower in NOACs versus warfarin (dabigatran: HR 0.50, 95 % CI: 0.40–0.62; rivaroxaban: HR 0.78, 95 % CI: 0.69–0.90); this risk was lower with dabigatran compared with rivaroxaban (HR 0.64, 95 % CI: 0.51─0.79). Net clinical benefit was superior to warfarin in both NOACs (dabigatran: HR 0.78, 95 % CI: 0.71–0.85; rivaroxaban: HR 0.83, 95 % CI: 0.78–0.88). Conclusions: Among real-world Japanese patients with AF and CAD, NOACs were associated with better clinical outcomes than warfarin. Treatment with dabigatran had a lower risk of major bleeding than rivaroxaban.Clinical trial registration: NCT05051904 (ClinicalTrials.gov)
- Published
- 2023
- Full Text
- View/download PDF
57. The prognostic value of ORBIT risk score in predicting major bleeding in patients with acute coronary syndrome.
- Author
-
Günlü, Serhat, Arpa, Abdulkadir, Kayan, Fethullah, Güzel, Tuncay, Kılıç, Raif, Aktan, Adem, Altintaş, Bernas, and Karahan, Mehmet Zülkif
- Subjects
- *
ACUTE coronary syndrome , *DISEASE risk factors , *PROGNOSIS , *RECEIVER operating characteristic curves , *HEMORRHAGE - Abstract
The most significant adverse effect of antithrombotic medication in acute coronary syndrome (ACS) is major bleeding, which is related to increased mortality. Studies on ORBIT risk score in predicting major bleeding in ACS patients are limited. This research aimed to examine whether the ORBIT score calculated at the bedside can identify major bleeding risk in patients with ACS. This research was retrospective, observational, and conducted at a single center. Analyses of receiver operating characteristics (ROC) were utilized to define the diagnostic value of CRUSADE and ORBIT scores. The predictive performances of the two scores were compared using DeLong's method. Discrimination and reclassification performances were evaluated by the integrated discrimination improvement (IDI), and net reclassification improvement (NRI). The study included 771 patients with ACS. The mean age was 68.7 ± 8.6 years, with 35.3 % females. 31 patients had major bleeding. Twenty-three of these patients were BARC 3 A, five were BARC 3 B, and three were BARC 3 C. Bleeding history [OR (95 % CI), 2.46 (1.02–5.94), p = 0.021], hemoglobin levels [OR (95 % CI), 0.54 (0.45–0.63), p < 0.001], and age > 74 years [OR (95 % CI), 1.03 (1.01–1.06), p = 0.039] were independent predictors of major bleeding. The ORBIT score was an independent predictor of major bleeding in the multivariate analysis: continuous variables [OR (95 % CI), 2.53 (2.61–3.95), p < 0.001] and risk categories [OR (95 % CI), 3.06 (1.69–5.52), p < 0.001]. Comparison of c-indexes for major bleeding events revealed a non-significant difference for the discriminative ability of the two tested scores (p = 0.07) with a continuous NRI of 6.6 % (p = 0.026) and an IDI of 4.2 % (p < 0.001). In ACS patients, the ORBIT score independently predicted major bleeding. • The ORBIT bleeding risk score is straightforward bedside methods for assessing patients with ACS. • ORBIT was the sole independent predictor of major bleeding, demonstrating a higher ability for distinguishing than CRUSADE. • The ORBIT score has 89 % specificity and 78 % sensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
58. Nonprocedural bleeding after left atrial appendage closure versus direct oral anticoagulants: A subanalysis of the randomized PRAGUE‐17 trial.
- Author
-
Branny, Marian, Osmancik, Pavel, Kala, Petr, Poloczek, Martin, Herman, Dalibor, Neuzil, Petr, Hala, Pavel, Taborsky, Milos, Stasek, Josef, Haman, Ludek, Chovancik, Jan, Cervinka, Pavel, Holy, Jiri, Kovarnik, Tomas, Zemanek, David, Havranek, Stepan, Vancura, Vlastimil, Peichl, Petr, Tousek, Petr, and Hozman, Marek
- Subjects
- *
HEMORRHAGE risk factors , *CONFIDENCE intervals , *ORAL drug administration , *GASTROINTESTINAL hemorrhage , *LEFT atrial appendage closure , *ANTICOAGULANTS , *SURGICAL complications , *ATRIAL fibrillation , *RISK assessment , *RESEARCH funding , *DESCRIPTIVE statistics , *DISEASE risk factors - Abstract
Introduction: Observational studies have shown low bleeding rates in patients with atrial fibrillation (AF) treated by left atrial appendage closure (LAAC); however, data from randomized studies are lacking. This study compared bleeding events among patients with AF treated by LAAC and nonvitamin K anticoagulants (NOAC). Methods: The Prague‐17 trial was a prospective, multicenter, randomized trial that compared LAAC to NOAC in high‐risk AF patients. The primary endpoint was a composite of a cardioembolic event, cardiovascular death, and major and clinically relevant nonmajor bleeding (CRNMB) defined according to the International Society on Thrombosis and Hemostasis (ISTH). Results: The trial enrolled 402 patients (201 per arm), and the median follow‐up was 3.5 (IQR 2.6–4.2) years. Bleeding occurred in 24 patients (29 events) and 32 patients (40 events) in the LAAC and NOAC groups, respectively. Six of the LAAC bleeding events were procedure/device‐related. In the primary intention‐to‐treat analysis, LAAC was associated with similar rates of ISTH major or CRNMB (sHR 0.75, 95% CI 0.44–1.27, p = 0.28), but with a reduction in nonprocedural major or CRNMB (sHR 0.55, 95% CI 0.31–0.97, p = 0.039). This reduction for nonprocedural bleeding with LAAC was mainly driven by a reduced rate of CRNMB (sHR for major bleeding 0.69, 95% CI 0.34–1.39, p =.30; sHR for CRNMB 0.43, 95% CI 0.18–1.03, p = 0.059). History of bleeding was a predictor of bleeding during follow‐up. Gastrointestinal bleeding was the most common bleeding site in both groups. Conclusion: During the 4‐year follow‐up, LAAC was associated with less nonprocedural bleeding. The reduction is mainly driven by a decrease in CRNMB. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
59. Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy.
- Author
-
Baturina, Olga, Chashkina, Maria, Andreev, Denis, Mirzaev, Karin, Bykova, Alexandra, Suvorov, Alexandr, Yeryshova, Daria, Suchkova, Svetlana, Sychev, Dmitry, and Syrkin, Abram
- Subjects
- *
ACUTE coronary syndrome , *FIBRINOLYTIC agents , *ATRIAL fibrillation , *HEMORRHAGE , *PATIENT experience - Abstract
Objective: This study's objective was to evaluate the effects of pharmacokinetic and pharmacogenetic factors on major bleeding in patients with ACS and non-valvular AF receiving combined antithrombotic therapy consisting of rivaroxaban, clopidogrel, and aspirin as part of dual or triple therapy. Methods: A prospective observational study was conducted in two PCI centers in Moscow, the Russian Federation, from 2017 to 2018. One hundred patients with ACS and AF were enrolled. Prospective follow-ups continued for 12 months. Results: A total of 36 patients experienced bleeding events, with 10 experiencing major bleeding based on the BARC scale and 17 experiencing major bleeding based on the ISTH scale. The following predictors associated with an increased number of major bleeding events were identified: for the ISTH scale, a Css min. of rivaroxaban of >137 pg/mL (5.94 OR, (95% CI, 3.13–12.99; p < 0.004)) and carriage of the T allelic variant polymorphism ABCB1 rs4148738 (8.97 OR (95% CI, 1.48–14.49; p < 0.017)), as well as for the BARC scale (5.76 OR (95% CI, 2.36–9.87; p < 0.018)). Conclusions: Measuring residual steady-state rivaroxaban concentrations and determining the carriage of the T allelic variant polymorphism ABCB1 rs4148738 may be applicable to high-risk patients for subsequent antithrombotic therapy modification. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
60. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
- Author
-
Roccograndi, Laura M., Lovell, Alexandra R., Ferrajoli, Alessandra, Thompson, Philip A., Burger, Jan A., Wierda, William G., Jain, Nitin, and Rausch, Caitlin R.
- Subjects
- *
CHRONIC lymphocytic leukemia , *ANTICOAGULANTS , *PLATELET aggregation inhibitors , *HEMORRHAGE , *ORAL medication , *CHRONIC leukemia - Abstract
Increased rates of clinically significant bleeding have been reported with ibrutinib, however, limited data is available on the risk when given with concomitant therapeutic anticoagulation. We analyzed the incidence of major bleeding in 64 patient exposures that received ibrutinib with concomitant therapeutic anticoagulation. Major bleeding was observed in 5/64 (8%) patient exposures. The highest incidence was observed with rivaroxaban (3/17, 18%), followed by apixaban (2/35, 6%). No major bleeding events were seen with enoxaparin (n = 10). A total of 38% of patient exposures received a concomitant antiplatelet agent along with therapeutic anticoagulation. Among these patients, one (4%) experienced a fatal hemorrhage while taking ibrutinib, apixaban, and clopidogrel concomitantly. Our retrospective study observed a higher rate of major hemorrhage with combined DOAC with ibrutinib than historically reported with ibrutinib alone. This combination may be associated with increased risk of major bleeding and further prospective studies evaluating this risk are necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
61. Real‐world decision‐making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience.
- Author
-
Grainger, Brian T., Merriman, Eileen, Royle, Gordon, Eaddy, Nicola, Ockelford, Paul, and Young, Laura
- Subjects
- *
THROMBOSIS , *HOSPITAL emergency services , *GASTROINTESTINAL hemorrhage , *INTRACRANIAL hemorrhage , *RETROSPECTIVE studies , *ACQUISITION of data , *HEMOSTASIS , *PROTHROMBIN , *RIVAROXABAN , *TRANEXAMIC acid , *TREATMENT effectiveness , *PUBLIC hospitals , *MEDICAL records , *DECISION making in clinical medicine , *METROPOLITAN areas , *HEMORRHAGE , *LONGITUDINAL method , *VITAMIN K - Abstract
Background: Rivaroxaban is used increasingly as an oral anticoagulant; however, a specific reversal agent is not currently available in the Australasian setting. There is also variation across international consensus guidelines regarding advice on the management of bleeding. Aims: To review the real‐world management of rivaroxaban‐associated major bleeding across the public hospitals of New Zealand's largest city. Methods: A retrospective cohort analysis was performed of patients prescribed rivaroxaban who presented to four metropolitan hospital Emergency Departments between 1 August 2018 and 31 May 2021 with major bleeding as defined by the International Society on Thrombosis and Haemostasis. Results: One hundred and twelve patients were identified, accounting for 115 major bleeding presentations. Upper gastrointestinal (34%) and intracranial (31%) bleeding sites were most common. Procedural intervention was required in 44% of patients. Haemostatic management involved tranexamic acid (TXA) in 26%, prothrombin complex concentrate (PCC) in 55% (dose range 1000–6000 IU or 10–65 IU/kg), vitamin K in 16% and fresh frozen plasma in 1%. Rivaroxaban was discontinued permanently following 56 (49%) events, switched to another anticoagulant in 24 (21%) and withheld in 30 (26%) from 2 days to 3 months (median 8.5 days). All‐cause mortality at 90 days after bleeding was 17% (19 patients), and the incidence of combined venous and arterial thrombotic events was 10%. Conclusions: There is considerable heterogeneity in the acute clinical management of patients presenting with rivaroxaban‐related major bleeding. The use of PCC and dosage administered is inconsistent. TXA was utilised in only approximately one‐quarter of all cases. Evidence‐based guidance for treating rivaroxaban‐related bleeding would improve the management of these patients and potentially improve clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
62. Efficacy and safety of vena cava filters in preventing pulmonary embolism: A systematic review and meta-analysis.
- Author
-
Miao, Huang-Tai, Li, Xiao-Ying, Zhou, Can, Liang, Ying, and Nie, Shao-Ping
- Subjects
- *
HEMORRHAGE risk factors , *SURGICAL instruments , *RELATIVE medical risk , *PULMONARY embolism , *META-analysis , *CONFIDENCE intervals , *SYSTEMATIC reviews , *RISK assessment , *TREATMENT effectiveness , *VENOUS thrombosis , *DESCRIPTIVE statistics , *RESEARCH funding , *VENA cava inferior , *PATIENT safety , *DISEASE risk factors - Abstract
Objectives: To assess the treatment effectiveness of inferior vena cava filters (IVCF) versus non-IVCF for patients undergoing varies conditions. Methods: We systematically searched the databases to identify eligible RCTs from their inception up to 9/20/2020. The primary endpoint was pulmonary embolism (PE), while the secondary endpoints included deep-vein thrombosis (DVT), major bleeding, and all-cause mortality. The RRs with 95% CIs were applied as effect estimates for the treatment effectiveness of IVCF versus non-IVCF and calculated by using the random-effects model. Results: 1,137 patients of 5 RCTs were enrolled. There were no significant differences between IVCF and non-IVCF for the risk of PE, major bleeding, and all-cause mortality, while the risk of DVT was significantly increased for patients treated with IVCF. Conclusions: The use of IVCF did not yield any benefits on PE, major bleeding, and all-cause mortality risk for patients undergoing various conditions, while the risk of DVT was significantly increased for patients treated with IVCF. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
63. Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients.
- Author
-
Choi, Eue‐Keun, Choi, Jong‐Il, Park, Hyoung‐Seob, Hwang, Gyo‐Seung, Joung, Boyoung, Kim, Jong‐Youn, Kim, Dae‐Hyeok, Shin, Dong Gu, and Park, Hyung Wook
- Subjects
HEMORRHAGE risk factors ,STROKE prevention ,DRUG efficacy ,RESEARCH ,CONFIDENCE intervals ,AGE distribution ,ATRIAL fibrillation ,ANTICOAGULANTS ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,RESEARCH funding ,LONGITUDINAL method ,EVALUATION - Abstract
Background: The real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population. Methods: One‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries. Results: Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (<65 years), youngest‐old (65–74 years) and middle‐old/oldest‐old (≥75 years) groups were 21.4%, 40.2%, and 38.4%, respectively. Incidence of major or clinically relevant nonmajor bleeding was similar within dose (0.57%–1.71%) and age subgroups (1.26%–1.63%). Incidence of net clinical outcome, a composite of stroke, systemic embolic event, major bleeding, and all‐cause mortality, was also comparable among dose subgroups (1.14%–3.10%) and age subgroups (2.28%–2.78%). The percentage of Korean patients receiving non‐recommended 30 mg (19.8%) was over twice that of the European population (8.4%). However, the clinical outcomes were generally similar among different populations included in the ETNA‐AF study. Conclusions: The outcomes in the Korean ETNA‐AF population are like those in the global ETNA‐AF population, with overall low event rates of stroke, major bleeding and all‐cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
64. Prognostic value of liver fibrosis assessed by the FIB-4 index in patients with acute coronary syndrome.
- Author
-
Cordero, Alberto, Escribano, David, Quintanilla, María Amparo, López-Ayala, José M., Masiá, María D., Cazorla, Diego, Martínez Rey-Rañal, Elías, Moreno-Arribas, José, and Zuazola, Pilar
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
65. Clinical Outcomes of Left Atrial Appendage Occlusion Versus Switch of Direct Oral Antcoagulant in Atrial Fibrillation: A Territory‐Wide Retrospective Analysis
- Author
-
Andrew Kei‐Yan Ng, Pauline Yeung Ng, April Ip, Raymond Chi‐Yan Fung, Shing‐Fung Chui, Chung‐Wah Siu, and Bryan P. Yan
- Subjects
atrial fibrillation ,direct oral anticoagulant ,left atrial appendage occlusion ,major bleeding ,mortality ,stroke ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Left atrial appendage occlusion (LAAO) has emerged as an alternative to oral anticoagulation therapy for stroke prevention in atrial fibrillation, but data comparing LAAO with direct oral anticoagulant (DOAC) are sparse. Methods and Results This cohort study compared LAAO (with or without prior anticoagulation) with a switch of one DOAC to another DOAC by 1:2 propensity score matching. The primary outcome was a composite of all‐cause mortality, ischemic stroke, and major bleeding. A total of 2350 patients (874 in the LAAO group and 1476 in the DOAC switch group) were included. After a mean follow‐up of 1052±694 days, the primary outcome developed in 215 (24.6%) patients in the LAAO group and in 335 (22.7%) patients in the DOAC switch group (hazard ratio [HR], 0.94 [95% CI, 0.80–1.12]; P=0.516). The LAAO group had a lower all‐cause mortality (HR, 0.49 [95% CI, 0.39–0.60]; P
- Published
- 2023
- Full Text
- View/download PDF
66. Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE Registry, a large observational study.
- Author
-
Terauchi, Yasuo, Inoue, Hiroshi, Yamashita, Takeshi, Akao, Masaharu, Atarashi, Hirotsugu, Ikeda, Takanori, Koretsune, Yukihiro, Okumura, Ken, Suzuki, Shinya, Tsutsui, Hiroyuki, Toyoda, Kazunori, Hirayama, Atsushi, Yasaka, Masahiro, Yamaguchi, Takenori, Teramukai, Satoshi, Kimura, Tetsuya, Morishima, Yoshiyuki, Takita, Atsushi, and Shimizu, Wataru
- Subjects
- *
GLYCOSYLATED hemoglobin , *OLDER patients , *ATRIAL fibrillation , *TREATMENT effectiveness , *INTRACRANIAL hemorrhage - Abstract
Background: This ANAFIE Registry sub-analysis investigated 2-year outcomes and oral anticoagulant (OAC) use stratified by glycated hemoglobin (HbA1c) levels among Japanese patients aged ≥ 75 years with non-valvular atrial fibrillation (NVAF) with and without clinical diagnosis of diabetes mellitus (DM). Methods: The ANAFIE Registry was a large-scale multicenter, observational study conducted in Japan; this sub-analysis included patients with baseline HbA1c data at baseline. The main endpoints evaluated (stroke/systemic embolic events [SEE], major bleeding, intracranial hemorrhage, cardiovascular death, all-cause death, and net clinical outcome [a composite of stroke/SEE, major bleeding, and all-cause death]) were stratified by HbA1c levels (< 6.0%; 6.0% to < 7.0%; 7.0% to < 8.0%; and ≥ 8.0%). Results: Of 17,526 patients with baseline HbA1c values, 8725 (49.8%) patients had HbA1c < 6.0%, 6700 (38.2%) had 6.0% to < 7.0%, 1548 (8.8%) had 7.0% to < 8.0%, and 553 (3.2%) had ≥ 8.0%. Compared with other subgroups, patients with HbA1c ≥ 8.0% were more likely to have lower renal function, higher CHA2DS2-VASc and HAS-BLED scores, higher prevalence of non-paroxysmal AF, and lower direct OAC (DOAC) administration, but higher warfarin administration. The HbA1c ≥ 8.0% subgroup had higher event rates for all-cause death (log-rank P = 0.003) and net clinical outcome (log-rank P = 0.007). Similar trends were observed for stroke/SEE. In multivariate analysis, risk of all-cause death (adjusted hazard ratio [aHR]: 1.46 [95% confidence interval 1.11–1.93]) and net clinical outcome (aHR 1.33 [1.05–1.68]) were significantly higher in the HbA1c ≥ 8.0% subgroup. No significant differences were observed in risks of major bleeding or other outcomes in this and other subgroups. No interaction was observed between HbA1c and OACs. Use/non-use of antidiabetic drugs was not associated with risk reduction; event risks did not differ with/without injectable antidiabetic drugs. Conclusions: Among elderly Japanese patients with NVAF, only HbA1c ≥ 8.0% was associated with increased all-cause death and net clinical outcome risks; risks of the events did not increase in other HbA1c subgroups. Relative event risks between patients treated with DOACs and warfarin were not modified by HbA1c level. Trial registration: UMIN000024006; date of registration: September 12, 2016. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
67. Frail patients who fall and their risk on major bleeding and intracranial haemorrhage. Outcomes from the Fall and Syncope Registry.
- Author
-
Zwart, LAR, Germans, T, Vogels, R, Simsek, S, Hemels, MEW, and Jansen, RWMM
- Subjects
FRAIL elderly ,CEREBRAL small vessel diseases ,SYNCOPE ,HEMORRHAGE - Abstract
Background: Major bleeding, and intracranial bleeding specifically, are severe complications related to the use of anticoagulation. To what extent the risk for major bleeding is elevated among frail older people is not well known because they are underrepresented in the randomized clinical trials (RCTs). This study investigates the risk for major bleeding (MB) and intra cranial haemorrhage (ICH) in frail older people who fall. Methods: All patients 65 years and older visiting the Fall and Syncope Clinic, between November 2011 and January 2020, and underwent a MRI of the brain were eligible. Frailty was assessed with a Frailty Index, based on the accumulation of deficits model. Cerebral small vessel disease was described and evaluated as proposed in the position paper of Wardlaw and colleagues in 2013. Results: 479 patients were included in this analysis. Mean follow-up was 7 years per patient (ranging from 1 month to 8 years and 5 months). 368 patients (77%) were frail. A total of 81 patients used oral anticoagulation (OAC). 17 extracranial MB of which 3 were traumatic and 14 gastrointestinal, and 16 ICH occurred. There was a total of 603.4 treatment years with OAC, and 8 MBs occurred among patients on OAC (bleeding rate 1.32 per 100 treatment years), of which 2 ICHs (bleeding rate 0.33 per 100 treatment years). The risk for extracranial MB was increased by the use of antiplatelet agents (APA) (adjusted OR 6.9, CI 95% 1.2–38.3), and by the use of OAC (adjusted OR 9.8, CI 95% 1.7–56.1). The risk for ICH was only heightened by white matter hyperintensities (WMH) (adjusted OR 3.8, CI 95% 1.0-13.4). The use of APA (adjusted OR 0.9, CI 95% 0.3–3.3) or OAC (adjusted OR 0.6, CI 95% 0.1–3.3) did not elevate the risk for ICH. Conclusion: In contrast to common belief, frail patients on OAC with repeated falls show a comparable bleeding rate as in the large RCTs, and the use of OAC did not increase the risk for ICH. However, the number of MBs was low, and of ICHs very low, despite extensive follow-up in this registry. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
68. Relation between laxative use and risk of major bleeding in patients with atrial fibrillation and heart failure.
- Author
-
Yamamoto, Jumpei, Yamamoto, Masaya, Hara, Hisao, and Hiroi, Yukio
- Subjects
- *
HEART failure , *ATRIAL fibrillation , *LAXATIVES , *HEMORRHAGE , *ORAL medication , *CONSTIPATION - Abstract
Constipation has been reported to increase the risk of cardiovascular mortality. Patients with atrial fibrillation (AF) and heart failure (HF) have more comorbidities and an increased bleeding risk. However, it remains unclear whether constipation is associated with an increased risk of incident bleeding complications in AF with HF. Here, we investigated the association between constipation requiring laxatives and major bleeding in AF and HF. We retrospectively analyzed the medical records of 370 consecutive patients hospitalized for AF and congestive HF. Constipation was defined as regularly taking laxatives or having at least two prescriptions for a ≥ 30-day supply of laxatives. Sixty patients experienced major bleeding events during a median follow-up of 318 days. The most common sites of bleeding were lower gastrointestinal (28%, 17/60), upper gastrointestinal (27%, 16/60), and intracranial (20%, 12/60). There were 33 (55%) patients with constipation in the bleeding group and 107 (35%) in the non-bleeding group (P = 0.004). Multivariate Cox regression analysis adjusted for HAS-BLED score, hemoglobin, and direct oral anticoagulant use showed that constipation (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.11–3.08; p = 0.019) was a significant risk factor for major bleeding. We found a significant association between constipation requiring laxatives and major bleeding in patients with AF and HF. These findings indicate the need for constipation prevention in these patients to avoid reliance on invasive defecation management, including laxatives. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
69. The Risk of Major Bleeding With Apixaban Administration in Patients With Acute Kidney Injury.
- Author
-
Givens, Gabrielle, Neu, Daniel, and Marler, Jacob
- Subjects
ACUTE kidney failure ,APIXABAN ,CHRONIC kidney failure ,ATRIAL fibrillation ,THROMBOEMBOLISM - Abstract
Background: Apixaban is eliminated by the kidneys and in acute kidney injury (AKI) there is potential for an increase in apixaban exposure and bleeding events. In one instance, data have shown higher than normal bleed risk in patients with AKI, unless calibrated anti-factor Xa monitoring is used, which is not widely available. Objective: To evaluate bleeding with apixaban administration to hospitalized patients with an AKI in an unmonitored real-world scenario. Methods: We conducted a retrospective study of patients admitted to a large urban academic teaching hospital from April 2015 to March 2022, who received apixaban for venous thromboembolism or nonvalvular atrial fibrillation (NVAF). The primary outcome evaluated major bleeding when apixaban was administered to patients with or without an AKI. Results: A total of 232 patients were evaluated (116 per group). Most patients (79.7%) were on apixaban for NVAF, 32.7% had chronic kidney disease, 58.2% were on a medication increasing bleed risk, and HAS-BLED score was a median of 2 in both groups. No differences were noted between groups for bleeding (AKI group 7.8% vs non-AKI 3.4%; P = 0.15), and on regression analysis, coadministration of a P2Y12 inhibitor was predictive of major bleeding (odds ratio = 5.9; 95% confidence interval = 1.4-23.6). Conclusion and Relevance: Although no differences between groups were noted, apixaban use in the AKI group resulted in a higher than normally reported incidence of apixaban-associated major bleeding, and concomitant antiplatelet use increased bleed risk as well. Cautious use of apixaban and further investigation with larger studies are warranted in this area. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
70. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition
- Author
-
Rolf Rossaint, Arash Afshari, Bertil Bouillon, Vladimir Cerny, Diana Cimpoesu, Nicola Curry, Jacques Duranteau, Daniela Filipescu, Oliver Grottke, Lars Grønlykke, Anatole Harrois, Beverley J. Hunt, Alexander Kaserer, Radko Komadina, Mikkel Herold Madsen, Marc Maegele, Lidia Mora, Louis Riddez, Carolina S. Romero, Charles-Marc Samama, Jean-Louis Vincent, Sebastian Wiberg, and Donat R. Spahn
- Subjects
Emergency medicine ,Trauma ,Traumatic coagulopathy ,Major bleeding ,Haemostasis ,Practice guideline ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Key messages Immediate detection and management of traumatic coagulopathy improves outcomes of severely injured patients. This guideline follows management of the severe trauma patient in chronological order, with a focus on prevention of possible exsanguination. These structured recommendations support measures that prioritise the optimisation of resources for the benefit of bleeding control based on scientific evidence. Empirical management should not be implemented unless no method of monitoring bleeding and coagulation is available. Optimal organisation of the resuscitation team for the bleeding trauma patient includes implementation of these guidelines.
- Published
- 2023
- Full Text
- View/download PDF
71. Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 – REGATA)
- Author
-
Ekaterina S. Kropacheva, Oxana A. Zemlyanskaya, Elena N. Krivosheeva, and Elizaveta P. Panchenko
- Subjects
resumption of anticoagulants ,major bleeding ,atrial fibrillation ,Medicine - Abstract
Background. It is necessary to strive to resume anticoagulants for patients with atrial fibrillation who have a high risk of thrombosis after the development of large bleeding. Due to the fact that death in these patients is caused not by a recurrence of fatal bleeding, but by the development of stroke in case of refusal of anticoagulant therapy. Aim. To evaluate the effect of the resumption of anticoagulant therapy on the risk of recurrence of major bleeding, thrombosis and death in patients with atrial fibrillation who have suffered major bleeding. Materials and methods. To evaluate the frequency of bleeding, thrombosis and death in patients with atrial fibrillation after major bleeding according to prospective follow-up data for one year. Results. The recurrence rate of major bleeding after the resumption of therapy was 21.7% per year. The frequency of fatal bleeding was 2.2%. In the anticoagulant withdrawal group, the incidence of thrombotic complications (ischemic stroke and myocardial infarction) was significantly higher compared to patients who resumed therapy. The frequency of death from all causes was significantly higher in the group of patients who did not resume anticoagulant therapy. Half of the deaths were due to cardiovascular causes. The presence of more than 5 points of the Charlson Comorbidity Index was a predictor of the development of the sum of all adverse events. Conclusion. The resumption of anticoagulant therapy after the development of major bleeding in patients with atrial fibrillation reduces the risk of thrombosis and death at a cost, while increasing the risk of recurrence of non-fatal bleeding.
- Published
- 2023
- Full Text
- View/download PDF
72. Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis
- Author
-
Huang, Wen‐Yi, Saver, Jeffrey L, Wu, Yi‐Ling, Lin, Chun‐Jen, Lee, Meng, and Ovbiagele, Bruce
- Subjects
Biomedical and Clinical Sciences ,Dentistry ,Cardiovascular ,Prevention ,Health Services ,Clinical Trials and Supportive Activities ,Clinical Research ,Hematology ,Heart Disease ,Heart failure ,Aspirin ,Meta-analysis ,Major bleeding ,Intracranial haemorrhage ,NOACs ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
AimsRelative bleeding risks of different antithrombotic agents in heart failure (HF) patients is an important consideration in treatment decision making, making detailed comparative analysis desirable. The aim of this study was to conduct a network meta-analysis to investigate the major bleeding risk for individual novel oral anticoagulants (NOACs) vs. aspirin among patients with HF.Methods and resultsWe searched Pubmed, EMBASE, Cochrane Collaboration Central Register of Controlled Clinical Trials, and Clinicaltrials.gov from 1966 to November 2019 to identify relevant randomized clinical trials. Studies comparing individual NOACs vs. aspirin were analysed using direct study-level meta-analysis. Studies comparing aspirin to warfarin and NOACs to warfarin were then additionally added using network (direct and indirect) study-level meta-analysis. Primary endpoint was major bleeding. Final analysis included nine trials with 34 367 participants, including one direct comparison trial (apixaban vs. aspirin) and eight indirect comparison trials against the shared warfarin comparator (four aspirin trials and one trial each of apixaban, dabigatran, rivaroxaban, and edoxaban). For apixaban, network meta-analysis combing direct and indirect comparison showed that major bleeding risk might not be different between apixaban and aspirin (odds ratio, 1.18 [95% confidence interval, 0.38 to 3.65]) in HF patients. In contrast, indirect-comparison meta-analysis showed dabigatran, rivaroxaban, and edoxaban compared with aspirin might be associated with a higher risk of major bleeding in HF patients.ConclusionsIn network meta-analysis, apixaban might be associated with a comparable risk of major bleeding compared with aspirin in patients with HF, while other NOACs might be associated with a higher risk. However, such results were not strongly convincing because of lack of direct comparison in an original trial and small sample size of trials and participants. A clinical trial directly comparing apixaban vs. aspirin in patients with HF and sinus rhythm may be worth undertaking.
- Published
- 2020
73. Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
- Author
-
Steven Deitelzweig, Amiee Kang, Jenny Jiang, Chuan Gao, Xuemei Luo, Nipun Atreja, Stella Han, Dong Cheng, Saarusri R Loganathan, and Gregory Y. H. Lip
- Subjects
direct oral anticoagulants ,non-valvular atrial fibrillation ,real world ,stroke ,major bleeding ,switching ,Medicine - Abstract
Background: Real-world evidence on direct oral anticoagulant outcomes among Non-Valvular Atrial Fibrillation (NVAF) patients is limited. We aimed to evaluate stroke/systemic embolism (SE) and major bleeding (MB) risks among NVAF patients continuing or switching to different oral anticoagulants. Methods: Using Optum’s de-identified Clinformatics® Data Mart Database, we identified NVAF patients initiating apixaban or rivaroxaban between 1 January 2013 and 31 December 2021. Patients switching therapies within 30 days before or 90 days after discontinuing their initial DOAC and those who continued initial therapy were included. The index date was the switch date for switchers, while continuers were assigned a hypothetic index date. Switchers and continuers were propensity score matched based on pre-index characteristics. Results: Among 167,868 apixaban and 65,888 rivaroxaban initiators, 2900 apixaban-to-rivaroxaban switchers were matched with 14,500 apixaban continuers, and 2873 rivaroxaban-to-apixaban switchers were matched with 14,365 rivaroxaban continuers. Apixaban-to-rivaroxaban switching was associated with higher stroke/SE risk (HR: 1.99, 95% CI: 1.38–2.88) and MB risk (HR:1.80, 95% CI: 1.46–2.23) than continuing apixaban. Rivaroxaban-to-apixaban switching had similar stroke/SE risk (HR: 0.74, 95% CI: 0.45–1.22) but lower MB risk (HR: 0.49, 95% CI: 0.38–0.65) than continuing rivaroxaban. Conclusions: These findings may aid physicians and patients in making informed decisions when considering a switch between apixaban and rivaroxaban.
- Published
- 2024
- Full Text
- View/download PDF
74. Clinical Course and Management of Patients with Emergency Surgery Treated with Direct Oral Anticoagulants or Vitamin K Antagonists—Results of the German Prospective RADOA-Registry
- Author
-
Jana Last, Eva Herrmann, Ingvild Birschmann, Simone Lindau, Stavros Konstantinides, Oliver Grottke, Ulrike Nowak-Göttl, Barbara Zydek, Christian von Heymann, Ariane Sümnig, Jan Beyer-Westendorf, Sebastian Schellong, Patrick Meybohm, Andreas Greinacher, and Edelgard Lindhoff-Last
- Subjects
emergency surgery ,direct oral anticoagulants ,vitamin K antagonists ,major bleeding ,prothrombin complex concentrate ,Medicine - Abstract
(1) Background: The clinical management of anticoagulated patients treated with direct oral anticoagulants (DOAC) or Vitamin K antagonists (VKA) needing emergency surgery is challenging. (2) Methods: The prospective German RADOA registry investigated treatment strategies in DOAC- or VKA-treated patients needing emergency surgery within 24 h after admission. Effectiveness was analysed by clinical endpoints including major bleeding. Primary observation endpoint was in hospital mortality until 30 days after admission. (3) Results: A total of 78 patients were included (DOAC: 44; VKA: 34). Median age was 76 years. Overall, 43% of the DOAC patients and 79% of the VKA patients were treated with prothrombin complex concentrates (PCC) (p = 0.002). Out of the DOAC patients, 30% received no hemostatic treatment compared to 3% (1/34) of the VKA patients (p = 0.002), and 7% of the DOAC patients and 21% of the VKA patients developed major or clinically relevant non-major bleeding at the surgical site (p = 0.093). In-hospital mortality was 13% with no significant difference between the two treatment groups (DOAC: 11%, VKA: 15%; p > 0.20). (4) Conclusions: The 30-day in-hospital mortality rate was comparable between both patient groups. VKA patients required significantly more hemostatic agents than DOAC patients in the peri- and postoperative surgery period.
- Published
- 2024
- Full Text
- View/download PDF
75. Adverse Events Requiring Hospitalization Following Catheter Ablation for Atrial Fibrillation in Heart Failure with versus without Systolic Dysfunction
- Author
-
Naoya Kataoka, Teruhiko Imamura, Takahisa Koi, Keisuke Uchida, and Koichiro Kinugawa
- Subjects
heart failure ,atrial fibrillation ,catheter ablation ,major bleeding ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: The safety and efficacy of atrial fibrillation (AF) ablation in individuals with heart failure (HF) with preserved ejection fraction (EF), particularly concerning the occurrence of post-procedural adverse events necessitating hospitalization, including anticoagulant-associated major bleeding, still lack conclusive determination. Methods: Data from patients with HF and AF who underwent catheter ablation for AF between 2019 and 2022 at our institution were retrospectively reviewed. All participants were divided into an EF < 50% group or an EF ≥ 50% group according to their baseline left ventricular EF. The composite incidence of the clinical events following catheter ablation was compared between the two groups: (1) all-cause death, (2) HF hospitalization, (3) stroke or systemic embolism, and (4) major bleeding. Results: A total of 122 patients (75 years old, 68 male) were included. Of them, 62 (50.8%) patients had an EF ≥ 50%. EF ≥ 50% was an independent predictor of the composite endpoint (adjusted odds ratio 6.07, 95% confidence interval 1.37–26.99, p = 0.018). The incidences of each adverse event were not significantly different between the two groups, except for a higher incidence of major bleeding in the EF ≥ 50% group (12.7% vs. 0%, p = 0.026). Conclusions: Among patients with HF coupled with AF, the incidence of adverse events following AF ablation proved notably elevated in patients with EF ≥ 50% in contrast to their counterparts with EF < 50%. This disparity primarily stems from a heightened occurrence of major bleeding within the EF ≥ 50% cohort. The strategy to reduce adverse events, especially in patients with EF ≥ 50%, remains the next concern.
- Published
- 2024
- Full Text
- View/download PDF
76. Comparison of bleeding risk scores and evaluation of major bleeding predictive factors in patients with major bleeding due to vitamin K antagonist use
- Author
-
Sinan Yildirim and Onur Aslan
- Subjects
Atrial fibrillation ,Vitamin K antagonist ,Major bleeding ,GARFIELD-AF ,HAS-BLED ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: Major bleeding in the treatment of atrial fibrillation is closely associated with an increased risk of death and major adverse outcomes in both the short and long term, but all bleeding events are associated with a reduced quality of life. Bleeding events are also known to reduce medication adherence. In this sense, bleeding risk scores are important tools to help predict major bleeding. However, it is not clear which scoring system is superior. Aim: In this study, our aim was to compare bleeding risk scores and to examine the factors associated with bleeding in patients with major bleeding while using vitamin K antagonists. Methods: In this retrospective and single-center study, scoring, laboratory and demographic data were analyzed with SPSS 20.0 statistical program. Results: The mean age of a total of 1434 patients included in our study was 68.2 ± 11.3 years, range was 39–93 years and 769 (53.6%) of these patients were male. Of 588 patients with major bleeding, 93 (15.8%) had intracranial hemorrhage. Logistic regression analysis comparing the scoring systems among themselves revealed that the GARFIELD-AF scoring system had a predictive effect on major bleeding independent of the effect of other scoring systems (OR: 1.532, 95% CI 1.348–1.741, p
- Published
- 2023
- Full Text
- View/download PDF
77. Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study.
- Author
-
Sombat, Benyapha, Tongkaew, Sarisa, Nilwaranon, Aticha, Mungthin, Mathirut, Jongcherdchootrakul, Kanlaya, and Lertwanichwattana, Teeraboon
- Subjects
- *
THERAPEUTIC complications , *WARFARIN , *INTERNATIONAL normalized ratio , *COHORT analysis , *ANTI-inflammatory agents - Abstract
Objectives: Warfarin, like many other anticoagulants, has been linked to an elevated risk of bleeding proportional to the amount of anticoagulation used. Not only was the incidence of bleeding raised by the dosage, but the subtherapeutic international normalized ratio (INR) was also associated with increased thrombotic events. This retrospective cohort and multi-center study evaluated the incidence and risk factors of warfarin therapy complications in community hospitals in Thailand's central and eastern regions from 2016 to 2021. Results: Among 335 patients (683.90 person-year of follow-up), The incidence rate of warfarin complications was 4.91 events per 100 person-year. The independent factor associated with warfarin therapy complications was propranolol prescription (Adjusted RR: 2.29, 95%CI: 1.12–4.71). The secondary analysis was divided according to the outcome of the major bleeding and thromboembolic event. Major bleeding events, hypertension (Adjusted RR: 0.40, 95%CI: 0.17–0.95), amiodarone prescription (Adjusted RR: 5.11, 95%CI: 1.08–24.15), and propranolol prescription (Adjusted RR: 2.86, 95%CI: 1.19–6.83) were the independent risk factors. While in the major thrombotic event, non-steroidal anti-inflammatory drugs (NSAIDs) prescription was an independent factor (Adjusted RR: 10.65, 95%CI: 1.26–90.35). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
78. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism.
- Author
-
Vedovati, Maria Cristina, Giustozzi, Michela, Munoz, Andrés, Bertoletti, Laurent, Cohen, Alexander T., Klok, Frederikus A., Connors, Jean M., Bauersachs, Rupert, Brenner, Benjamin, Campanini, Mauro, Becattini, Cecilia, and Agnelli, Giancarlo
- Subjects
- *
THROMBOEMBOLISM , *VENOUS thrombosis , *DISEASE relapse , *GASTROINTESTINAL hemorrhage , *HEMORRHAGE , *GASTROINTESTINAL cancer - Abstract
• 1155 patients with cancer-associated VTE receiving dalteparin or apixaban from the randomized Caravaggio study. • Recurrent VTE occurred in 78 patients (6.8%) and major bleeding in 45 (3.9%). • Pancreatic or hepatobiliary cancer, increase in creatinine clearance, ECOG status of at least 1, index DVT and anti-cancer treatment were independent predictors for recurrent VTE. • ECOG status of 2, genitourinary cancer, upper and non-resected luminal gastrointestinal cancer were independent predictors of major bleeding. Risks of recurrence and treatment-emergent bleeding are high in patients with cancer-associated venous thromboembolism (VTE) but factors associated with these risks remain substantially undefined. The aim of this analysis in patients with cancer-associated VTE included in the Caravaggio study was to identify risk factors for recurrent VTE and major bleeding. Variables potentially predictive for recurrent VTE or major bleeding were evaluated in a Cox proportional hazard multivariable analysis with backward variable selection. Recurrent VTE occurred in 78 patients (6.8%) and major bleeding in 45 (3.9%). Independent risk factors for recurrent VTE were deep vein thrombosis (DVT) as index event (Hazard ratio (HR) 1.84, 95% CI 1.17–2.88), ECOG status of 1 or more (HR 1.95, 95% CI 1.11–3.43), pancreatic or hepatobiliary cancer site (HR 2.20, 95% CI 1.19–4.06), concomitant anti-cancer treatment (HR 1.98, 95% CI 1.03–3.81) and creatinine clearance (HR 1.10, 95% CI 1.00–1.20 for every 10 ml/min absolute increase). Independent risk factors for major bleeding were ECOG status of 2 (HR 2.31, 95% CI 1.24–4.29), genitourinary cancer site (HR 2.72, 95% CI 1.28–5.77), upper gastrointestinal cancer site (HR 3.17, 95% CI 1.22–8.23), and non-resected luminal gastrointestinal cancer (HR 2.77, 95% CI 1.38–5.56). This analysis of the Caravaggio study in patients with cancer-associated VTE who were on standardized anticoagulant treatment identified five independent predictors for recurrent VTE and four independent predictors of treatment-emergent major bleeding. Considering these risks could help clinicians to optimize the anticoagulant treatment in patients with cancer-associated VTE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
79. Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis.
- Author
-
Troisi, Federica, Guida, Pietro, Vitulano, Nicola, Quadrini, Federico, Di Monaco, Antonio, and Grimaldi, Massimo
- Subjects
- *
ANTICOAGULANTS , *ORAL medication , *ATRIAL fibrillation , *ELECTRIC countershock , *TRANSIENT ischemic attack - Abstract
A systematic evaluation focused on efficacy and safety for electrical cardioversion of atrial fibrillation (AF) among different Direct Oral Anticoagulants (DOACs) has not been previously performed. In this setting, we conducted a meta-analysis of studies evaluating DOACs vs vitamin K antagonists (VKA) as common comparator. We searched Cochrane Library, Pubmed, Web Of Science and Scopus databases for all English-only articles concerning studies that have estimated the effect of DOACs and VKA on stroke, transient ischemic attack or systemic embolism (SSE) and major bleeding (MB) events in AF patients undergoing electrical cardioversion. We selected 22 articles comprising 66 cohorts and 24,322 procedures (12,612 with VKA). During follow-up (studies' median 42 days), 135 SSE (52 DOACs and 83 VKA) and 165 MB (60 DOACs and 105 VKA) were recorded. The overall pooled effects, DOACs vs VKA, was estimated by an univariate Odds Ratio of 0.92 (0.63–1.33; p = 0.645) for SSE and 0.58 (0.41–0.82; p = 0.002) for MB; at bivariate evaluation, adjusting for study type, were respectively 0.94 (0.55–1.63; p = 0.834) and 0.63 (0.43–0.92, p = 0.016). Each single DOAC showed similar and non statistically different results in outcome occurrence compared to VKA as well as when Apixaban, Dabigatran, Edoxaban and Rivaroxaban were indirectly compared to each other. In patients undergoing electrical cardioversion, compared to VKA, DOACs have similar thromboembolic protection with lower major bleeding incidence. Single molecule does not show difference in event rate compared to each other. Our findings, provide useful information about safety and efficacy profile of DOACs and VKA. • Direct Oral Anticoagulants (DOACs) have entered in clinical practice for a decade. • Vitamin K antagonists (VKA) is the traditional oral anticoagulant therapy. • Cardioversion for atrial fibrillation requires a therapeutic anticoagulation. • Efficacy and safety of DOACs vs VKA were compared by meta-analysis of 22 studies. • Thromboembolic protection and major bleeding were not different among molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
80. Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants.
- Author
-
Sairaku, Akinori and Nakano, Yukiko
- Subjects
- *
KIDNEY physiology , *CLINICAL drug trials , *ORAL drug administration , *AGE distribution , *ATRIAL fibrillation , *ANTICOAGULANTS , *MARKETING , *PLATELET aggregation inhibitors , *DRUG interactions , *HEMORRHAGE - Abstract
Large-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants (DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since 2011 in Japan, and the results of the last one have recently been published. Each reported a more than acceptable ischemic stroke prevention. The major bleeding rates were also acceptably low and comparable to each other in the PMSSs of dabigatran (J-dabigatran), rivaroxaban (XAPASS), and edoxaban (ETNA-AF-Japan). However, the incidence in PMSS of apixaban (STANDARD) was more than double the others. This finding appeared to contradict the globally accepted theory that apixaban is less likely than other DOACs to cause bleeding events. Possible responsible mechanisms included (1) the age and kidney function, (2) concomitant antiplatelet therapy, (3) drug actions, (4) follow-up duration, and (5) dose reduction criteria. Similarities in the clinical background shared by the 4 different PMSSs' participants and knowledge from previous studies did not support a dominant contribution of any of those former 4 factors to the increased major bleeding incidence in STANDARD. A possibility of the 5th factor was then examined. An estimated calculation we created showed that apixaban's dose reduction criteria was strict enough to considerably reduce the opportunity for participants to take its reduced rather than standard dose. We then successfully simulated how the "strict" dose reduction criteria would have increased the bleeding event rates under DOAC therapy. The discussion in this review may therefore raise a question about the validity of the current dose reduction criteria of apixaban for Japanese AF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
81. Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study.
- Author
-
Wu, Shuyi, Guan, Chengfu, Xu, Wenlin, Zhang, Feilong, Huang, Nianxu, Chen, Xia, Zhang, Wang, Hu, Wei, Su, Jun, Dai, Hengfen, Gu, Ping, Huang, Xiaohong, Du, Xiaoming, Li, Ruijuan, Zheng, Qiaowei, Lin, Xiangsheng, Zhang, Yanxia, Zou, Lang, Liu, Yuxin, and Zhang, Min
- Subjects
- *
HEMORRHAGE risk factors , *DRUG efficacy , *RESEARCH , *HOSPITALS , *PYRIDINE , *CONFIDENCE intervals , *RADIO frequency therapy , *ATRIAL fibrillation , *CATHETER ablation , *ANTICOAGULANTS , *HEALTH status indicators , *RETROSPECTIVE studies , *ACQUISITION of data , *BENZIMIDAZOLES , *MATHEMATICAL variables , *RIVAROXABAN , *MEDICAL records , *ODDS ratio , *PATIENT safety , *LONGITUDINAL method , *EVALUATION - Abstract
Background: Based on the few available studies on the prognostic benefit of using direct oral anticoagulants (DOACs) after atrial fibrillation (AF) ablation. Therefore, this study aimed to evaluate the prognostic differences between patients who underwent radiofrequency ablation (RFA) and those without RFA taking DOACs. Methods: This is a multicenter retrospective cohort study enrolling 6137 patients with non-valvular AF (NVAF) at 15 hospitals in China. Patient information was collected through a mean follow-up of 10 months and medical record queries. Clinical outcomes included major bleeding, total bleeding, thrombosis, all-cause death, and a composite endpoint of bleeding, thrombosis, and all-cause death. Results: After adjusting for confounders and propensity score matching (PSM), patients with RFA of NVAF had a significantly lower risk of major bleeding [OR 0.278 (95% CI, 0.150-0.515), P<0.001], thrombosis [OR 0.535 (95% CI, 0.316-0.908), P=0.020] and the composite endpoint [ OR 0.835 (95% CI, 0.710-0.982), P=0.029]. In the RFA PSM cohort, dabigatran was associated with reduced all-cause death in patients with RFA of NVAF [OR 0.420 (95% CI, 0.212-0.831), P=0.010]. In the no RFA PSM cohort, rivaroxaban was associated with a reduction in major bleeding [OR 0.521 (95% CI, 0.403-0.673), P<0.001], total bleeding [OR 0.114 (95% CI, 0.049-0.266), P<0.001], and the composite endpoint [OR 0.659 (95% CI, 0.535-0.811), P<0.001]. Conclusion: Among patients with NVAF treated with DOACs, RFA was a negative correlate of major bleeding, thrombosis, and composite endpoints but was not associated with total bleeding or all-cause mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
82. New score for predicting major bleeding in patients with atrial fibrillation using direct oral anticoagulants.
- Author
-
Chen, Jiana, Lv, Meina, Xu, Wenlin, Zhang, Feilong, Huang, Nianxu, Chen, Xia, Zhang, Wang, Hu, Wei, Su, Jun, Dai, Hengfen, Gu, Ping, Huang, Xiaohong, Du, Xiaoming, Li, Ruijuan, Zheng, Qiaowei, Lin, Xiangsheng, Zhang, Yanxia, Liu, Yuxin, Zhang, Min, and Liu, Xiumei
- Subjects
- *
ATRIAL fibrillation , *ORAL medication , *HEMORRHAGE , *GASTROINTESTINAL agents , *CHINESE people - Abstract
Our aim was to identify factors associated with major bleeding in patients with atrial fibrillation (AF) on direct oral anticoagulants (DOACs) and to construct and externally validate a predictive model that would provide a validated tool for clinical assessment of major bleeding. In the development cohort, prediction model was built by logistic regression, the area under the curve (AUC), and Nomogram. External validation, analytical identification and calibration of the model using AUC, calibration curves and Hosmer-Lemeshow test. The development cohort consisted of 4209 patients from 7 centers and the external validation cohort consisted of 1800 patients from 12 centers. Multifactorial analysis showed that age > 65 years, history of bleeding, anemia, vascular disease, antiplatelet therapy/non-steroidal anti-inflammatory drugs and rivaroxaban were independent risk factors for major bleeding, and gastrointestinal protective agents was a protective factor. The Alfalfa-MB model was constructed using these seven factors (AUC = 0.807), and in the external validation cohort, the model showed good discriminatory power (AUC = 0.743) and good calibration (Hosmer-Lemeshow test P value of 0.205). The predictive power of the six bleeding scores was ORBIT (AUC = 0.706), HAS-BLED (AUC = 0.648), ATRIA (AUC = 0.645), HEMORR2 HAGES (AUC = 0.632), ABC (AUC = 0.619) and Shireman (AUC = 0.599) in descending order. Based on 7 factors, we derived and externally validated a predictive model for major bleeding with DOACs in patients with AF (Alfalfa-MB). The model has good predictive value and may be an effective tool to help reduce the occurrence of major bleeding in patients with DOACs. • New major bleeding score in a Chinese population with atrial fibrillation. • Model of bleeding in patients with atrial fibrillation on direct oral anticoagulants. • Develop the model in multiple centers and validate the model externally. • Several typical atrial fibrillation bleeding models were validated and compared. • This model can provide a new reference for predicting bleeding in clinical. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
83. Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis.
- Author
-
Vedovati, Maria Cristina, Graziani, Mara, Agnelli, Giancarlo, and Becattini, Cecilia
- Abstract
Venous thromboembolism (VTE) is common in patients with coronavirus disease-2019 (COVID-19). The optimal heparin regimen remains unknown and should balance thromboembolic and bleeding risks. The aim of this study was to evaluate the efficacy and safety of standard or higher heparin regimens for the prevention of VTE in patients hospitalized due to COVID-19. We performed a systematic literature search; studies reporting on hospitalized patients with COVID-19 who received standard heparin prophylaxis vs. high (intermediate or therapeutic) heparin regimens were included if outcome events were reported by treatment group and more than 10 patients were included. Primary study outcome was in-hospital VTE. Secondary study outcomes were major bleeding (MB), all-cause death, fatal bleeding and fatal pulmonary embolism. Overall, 33 studies (11,387 patients) were included. Venous thromboembolic events occurred in 5.2% and in 8.2% of patients who received heparin prophylaxis with at high-dose or standard-dose, respectively (RR 0.71, 95% CI 0.55–0.90, I2 48.8%). MB was significantly higher in patients who received high- compared to the standard-dose (4.2% vs 2.2%, RR 1.94, 95% CI 1.47–2.56, I2 18.1%). Sub-analyses showed a slight benefit associated with high-dose heparin in patients admitted to non-intensive care unit (ICU) but not in those to ICU. No significant differences were observed for mortality outcomes. Heparin prophylaxis at high-dose reduces the risk of VTE, but increased the risk of MB compared to the standard-dose. No clinical benefit for heparin high-dose was observed for ICU setting, but its role in the non-ICU deserves further evaluation. PROSPERO registration number: CRD42021252550. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
84. Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
- Author
-
Cohen, Alexander T., Sah, Janvi, Dhamane, Amol D., Hines, Dionne M., Lee, Theodore, Rosenblatt, Lisa, Emir, Birol, Keshishian, Allison, Yuce, Huseyin, and Luo, Xuemei
- Abstract
Introduction: Patients at increased risk of bleeding and recurrent VTE who develop venous thromboembolism (VTE) present challenges for clinical management. This study evaluated the effectiveness and safety of apixaban vs warfarin in patients with VTE who have risk factors for bleeding or recurrences. Methods: Adult patients with VTE initiating apixaban or warfarin were identified from five claims databases. Stabilized inverse probability treatment weighting (IPTW) was used to balance characteristics between cohorts for the main analysis. Subgroup interaction analyses were conducted to evaluate treatment effects among patients with and without each of the conditions that increased the risk of bleeding (thrombocytopenia and history of bleed) or recurrent VTE (thrombophilia, chronic liver disease, and immune-mediated disorders). Results: A total of 94,333 warfarin and 60,786 apixaban patients with VTE met selection criteria. After IPTW, all patient characteristics were balanced between cohorts. Apixaban (vs warfarin) patients were at lower risk of recurrent VTE (HR [95% confidence interval (CI) 0.72 [0.67–0.78]), major bleeding (MB) (HR [95% CI] 0.70 [0.64–0.76]), and clinically relevant non-major (CRNM) bleeding (HR [95% CI] 0.83 [0.80–0.86]). Subgroup analyses showed generally consistent findings with the overall analysis. For most subgroup analyses, there were no significant interactions between treatment and subgroup strata on VTE, MB and CRNM bleeding. Conclusion: Patients with prescription fills for apixaban had lower risk of recurrent VTE, MB, and CRNM bleeding compared with warfarin patients. Treatment effects of apixaban vs warfarin were generally consistent across subgroups of patients at increased risk of bleeding/recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
85. Predicting In Vivo Drug–Drug Interactions Between Rivaroxaban and Tyrosine Kinase Inhibitors Arising from Mechanism-Based Inactivation of Cytochrome P450 3A4
- Author
-
Shuen, Ng Wei, Weihan, Hou, Jerry, Choo Jun An, Guo, Huaqun, editor, Ren, Hongliang, editor, Wang, Victor, editor, Chekole, Eyasu Getahun, editor, and Lakshmanan, Umayal, editor
- Published
- 2022
- Full Text
- View/download PDF
86. Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials
- Author
-
Shane Parfrey, Amr Abdelrahman, Daniel Blackman, Jonathan M. Blaxill, Michael S. Cunnington, John P. Greenwood, Christopher J. Malkin, Abdul M. Mozid, Jennifer A. Rossington, Murugapathy Veerasamy, Nancy Wassef, Stephen B. Wheatcroft, and Heerajnarain Bulluck
- Subjects
Dual antiplatelet therapy ,Percutaneous coronary intervention, one-month ,Major bleeding ,Mortality ,Myocardial infarction ,Stent thrombosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Very short duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has recently attracted a lot of attention with the introduction of newer generations stents. This is appealing, especially in patients at high bleeding risk. However, none of the trials were powered for the individual ischemic and bleeding endpoints. All randomised controlled trials (RCTs) investigating one-month versus routine duration of DAPT in patients undergoing PCI and reporting outcomes from the time of cessation of DAPT (1 month) to 1 year were eligible for inclusion in the meta-analysis. The pooled risk ratios (RR) with their 95% confidence interval (CI) were calculated with the random-effects model using the Mantel-Haenszel method. Four RCTs involving 26,576 patients were included in this meta-analysis. Cessation of DAPT after 1 month was associated with significantly less major bleeding [RR 0.70, 95%CI (0.51–0.95), P = 0.02, heterogeneity (I2) = 42%]. There was no statistically significant difference in all-cause mortality [RR 0.84 (95%CI 0.69–1.03), P = 0.10, I2 = 0%] and stroke [RR 0.71 (95%CI 0.45–1.13), P = 0.15, I2 = 42%] when compared to routine duration of DAPT. There was also no difference in myocardial infarction (MI) [RR 1.12 (95%CI 0.91–1.39), P = 0.28, I2 = 0%], and definite or probable stent thrombosis [RR 1.49 (95%CI 0.92–2.41), P = 0.11, I2 = 0%] with cessation of DAPT after 1 month. Cessation of DAPT 1 month after PCI was associated with significantly less major bleeding, but there was no difference in the rate of all-cause mortality, stroke, MI and stent thrombosis.
- Published
- 2022
- Full Text
- View/download PDF
87. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition.
- Author
-
Rossaint, Rolf, Afshari, Arash, Bouillon, Bertil, Cerny, Vladimir, Cimpoesu, Diana, Curry, Nicola, Duranteau, Jacques, Filipescu, Daniela, Grottke, Oliver, Grønlykke, Lars, Harrois, Anatole, Hunt, Beverley J., Kaserer, Alexander, Komadina, Radko, Madsen, Mikkel Herold, Maegele, Marc, Mora, Lidia, Riddez, Louis, Romero, Carolina S., and Samama, Charles-Marc
- Abstract
Background: Severe trauma represents a major global public health burden and the management of post-traumatic bleeding continues to challenge healthcare systems around the world. Post-traumatic bleeding and associated traumatic coagulopathy remain leading causes of potentially preventable multiorgan failure and death if not diagnosed and managed in an appropriate and timely manner. This sixth edition of the European guideline on the management of major bleeding and coagulopathy following traumatic injury aims to advise clinicians who care for the bleeding trauma patient during the initial diagnostic and therapeutic phases of patient management. Methods: The pan-European, multidisciplinary Task Force for Advanced Bleeding Care in Trauma included representatives from six European professional societies and convened to assess and update the previous version of this guideline using a structured, evidence-based consensus approach. Structured literature searches covered the period since the last edition of the guideline, but considered evidence cited previously. The format of this edition has been adjusted to reflect the trend towards concise guideline documents that cite only the highest-quality studies and most relevant literature rather than attempting to provide a comprehensive literature review to accompany each recommendation. Results: This guideline comprises 39 clinical practice recommendations that follow an approximate temporal path for management of the bleeding trauma patient, with recommendations grouped behind key decision points. While approximately one-third of patients who have experienced severe trauma arrive in hospital in a coagulopathic state, a systematic diagnostic and therapeutic approach has been shown to reduce the number of preventable deaths attributable to traumatic injury. Conclusion: A multidisciplinary approach and adherence to evidence-based guidelines are pillars of best practice in the management of severely injured trauma patients. Further improvement in outcomes will be achieved by optimising and standardising trauma care in line with the available evidence across Europe and beyond. Key messages: Immediate detection and management of traumatic coagulopathy improves outcomes of severely injured patients. This guideline follows management of the severe trauma patient in chronological order, with a focus on prevention of possible exsanguination. These structured recommendations support measures that prioritise the optimisation of resources for the benefit of bleeding control based on scientific evidence. Empirical management should not be implemented unless no method of monitoring bleeding and coagulation is available. Optimal organisation of the resuscitation team for the bleeding trauma patient includes implementation of these guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
88. Improving risk prediction for death, stroke and bleeding in Asian patients with atrial fibrillation.
- Author
-
Krittayaphong, Rungroj, Kanjanarutjawiwat, Wiwat, Wisaratapong, Treechada, and Lip, Gregory Y. H.
- Subjects
- *
ATRIAL fibrillation , *ASIANS , *DEATH forecasting , *STROKE , *DISEASE risk factors - Abstract
Background: The objectives of this study were to compare the GARFIELD Refitted model and CHA2DS2‐VASc/HAS‐BLED risk scores with the new model from the COOL‐AF registry for all‐cause death, ischaemic stroke/systemic embolism (SSE) and major bleeding in Asian patients with atrial fibrillation (AF). Methods: Patients with non‐valvular AF in the nationwide COOL‐AF registry were studied. Patients were enrolled from 27 hospitals in Thailand during 2014–2017. Main outcomes were all‐cause mortality, SSE and major bleeding. Predictive models of the three outcomes were developed from the variables in the multivariable Cox‐proportional Hazard model. Predictive values of the models were evaluated by C‐statistics, calibration plots and decision curve analysis (DCA). The new COOL‐AF models were compared with the GARFIELD Refitted models and CHA2DS2‐VASc model for all‐cause mortality, SSE/HAS‐BLED model for major bleeding. Results: A total of 3405 patients were enrolled. The C‐statistics for the COOL‐AF models were 0.727 (0.712–0.742), 0.708 (0.693–0.724) and 0.706 (0.690–0.721) for all‐cause mortality, SSE and major bleeding, respectively. Calibration plots showed good agreement between predicted probability the observed outcomes for the COOL‐AF models with a calibration slope of 0.94–0.99. The predictive ability remains preserved after the internal validation with bootstraps and optimism (bias) correction. The COOL‐AF predictive models tended to be superior to the GARFIELD Refitted, CHA2DS2‐VASc and HAS‐BLED models. Conclusion: The COOL‐AF predictive models for all‐cause mortality, SSE and major bleeding in Asian patients with AF had a good predictive ability. The COOL‐AF model for all‐cause mortality was superior to the GARFIELD Refitted and CHA2DS2‐VASc model. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
89. Effect of fibrinogen replacement therapy on bleeding outcomes and 1-year mortality in patients undergoing thoracic aortic surgery: a retrospective cohort study.
- Author
-
Kikura, Mutsuhito, Tobetto, Yoko, Yamamoto, Kaori, Uraoka, Masahiro, and Go, Ritsuko
- Subjects
- *
FIBRINOGEN , *COHORT analysis , *CARDIOPULMONARY bypass , *HEMORRHAGE , *BLOOD transfusion , *THORACIC surgery , *THROMBELASTOGRAPHY - Abstract
Purpose: This study aimed to examine the effect of fibrinogen replacement therapy with cryoprecipitate or fibrinogen concentrate on bleeding outcomes and 1-year mortality in patients undergoing thoracic aortic surgery. Methods: We retrospectively studied 439 consecutive patients who underwent thoracic aortic surgery with cardiopulmonary bypass between January 1st, 2010 and December 31st, 2019 and identified patients who received cryoprecipitate or fibrinogen concentrate (the fibrinogen replacement group) and those who did not (the control group). Multivariate analyses were performed to examine the associations of fibrinogen replacement therapy with perioperative major bleeding (i.e., excessive hemorrhage or blood transfusion), re-exploration for bleeding, and 1-year mortality. Results: There were 285 patients in the fibrinogen replacement group who received 2.2 ± 1.0 g of concentrated fibrinogen amount and 154 patients in the control group. The incidence of major bleeding in the fibrinogen replacement group was less than that in the control group in patients with fibrinogen level < 150 mg/dL during cardiopulmonary bypass (49.7% versus 74.6%, p = 0.0007, multivariate odds ratio; 0.33, 95% confidence intervals; 0.12–0.91, p = 0.03), but not in patients with fibrinogen level ≥ 150 mg/dL (25.0% versus 29.6%, p = 0.51). No significant difference was found in re-exploration for bleeding (1.0% versus 1.3%, p = 1.00) or 1-year mortality (10.4% versus 5.3%, multivariate Cox proportional-hazard ratio; 1.03, 95% confidence intervals; 0.82–1.31, p = 0.74) between the fibrinogen replacement group and the control group. Conclusions: The results of this study indicate that 2–3 g of fibrinogen replacement reduces the incidence of major bleeding in patients with hypofibrinogenemia during cardiopulmonary bypass in thoracic aortic surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
90. Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents.
- Author
-
Al Aseri, Zohair, AlGahtani, Farjah H., Bakheet, Majid F., Al-Jedai, Ahmed H., and Almubrik, Sarah
- Subjects
ORAL medication ,EVIDENCE-based management ,RODENTICIDES ,ANTICOAGULANTS ,HEMORRHAGE ,INTRACRANIAL hemorrhage - Abstract
The indications of direct oral anticoagulants (DOACs) have expanded over the past 15 years. DOACs are effective and safe oral anticoagulants associated with lower bleeding risks and mortality than vitamin K antagonists. However, DOAC users are prone to a considerable bleeding risk, which can occur at critical sites or lead to severe life-threatening conditions. Recent statistics indicated that major bleeding occurs in up to 6.62 DOAC users per 100 treatment years. With the increased use of DOACs in clinical practice, DOAC-associated major bleeding is expected to be encountered more frequently in the emergency department. The current international guidelines recommend specific reversal agents for the management of DOAC users with severe bleeding to reverse the anticoagulant effect and restore normal hemostasis. An individualized assessment was incorporated in specific clinical situations to guide the decision pathway of major bleeding management. However, specific reversal agents are unavailable or have limited availability in many countries, which is expected to negatively impact the clinical outcomes of DOAC-associated major bleeding. Limited real-world evidence is available from these countries regarding the clinical outcomes of patients with DOAC-associated major bleeding. This narrative review provided an updated assessment of the evidence-based approaches for the management of major bleeding in DOAC users. We also explored the clinical outcomes of patients with major bleeding from clinical settings where specific reversal agents are unavailable. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
91. Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL‐AF Registry
- Author
-
Rungroj Krittayaphong, Arjbordin Winijkul, Komsing Methavigul, and Gregory Y. H. Lip
- Subjects
ABC pathway ,death ,ischemic stroke ,major bleeding ,systolic blood pressure ,time in therapeutic range ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background We aimed to determine the effect of integrating Atrial Fibrillation Better Care pathway compliance in relation to achievement of systolic blood pressure (SBP) targets and good control of time in therapeutic range (TTR) on clinical outcomes in patients with atrial fibrillation. Methods and Results We prospectively enrolled patients with nonvalvular atrial fibrillation from 27 hospitals in Thailand. All clinical outcomes were recorded. Main outcomes were the composite of all‐cause death or ischemic stroke/systemic embolism (SSE), as well as secondary outcomes of all‐cause death, SSE, major bleeding, intracranial hemorrhage, and heart failure. An SBP of 120 to 140 mm Hg was considered good blood pressure control. Target TTR was a TTR ≥65%. A total of 3405 patients were studied (mean age 67.8 years, 41.8% female). Full ABC pathway compliance was evident in 42.7%. For blood pressure control, 41.9% had SBP within target, whereas 35.9% of those on warfarin had TTR within target. The incidence rates of all‐cause death/SSE, all‐cause death, SSE, major bleeding, intracranial hemorrhage, and heart failure were 5.29, 4.21, 1.51, 2.25, 0.78, and 2.84 per 100 person‐years respectively. Adjusted hazard ratios and 95% CI of Atrial Fibrillation Better Care pathway compliance for all‐cause death/SSE, all‐cause death, and heart failure were 0.76 (0.62–0.94), 0.79 (0.62–0.99), and 0.69 (0.51–0.94), respectively, compared with noncompliance. Patients with Atrial Fibrillation Better Care compliance and SBP within target had a better outcome or TTR within target had better outcomes. Conclusions In COOL‐AF (Cohort of Antithrombotic Use and Optimal International Normalized Ratio Level in Patients With Non‐Valvular Atrial Fibrillation in Thailand), a multicenter nationwide prospective cohort of patients with atrial fibrillation, achieving SBP within target and TTR ≥ 65% has added value to Atrial Fibrillation Better Care pathway compliance in the reduction of adverse clinical outcomes in patients with atrial fibrillation.
- Published
- 2023
- Full Text
- View/download PDF
92. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis.
- Author
-
Lee, Kun-Han, Chen, Ying-Fan, Yeh, Wan-Yu, Yeh, Jiunn-Tyng, Yang, Tzu-Han, Chou, Chian-Ying, Chang, Yuh-Lih, Wang, Wei-Ting, Chiang, Chern-En, Chen, Chen-Huan, and Cheng, Hao-Min
- Subjects
- *
STROKE prevention , *MEDICAL databases , *CAUSES of death , *META-analysis , *MEDICAL information storage & retrieval systems , *CONFIDENCE intervals , *SYSTEMATIC reviews , *INTRACRANIAL hemorrhage , *GASTROINTESTINAL hemorrhage , *ATRIAL fibrillation , *ANTICOAGULANTS , *TREATMENT effectiveness , *ASPIRIN , *DESCRIPTIVE statistics , *MEDLINE , *ODDS ratio , *VITAMIN K , *CHEMICAL inhibitors , *DISEASE risk factors , *DISEASE complications , *OLD age ,STROKE risk factors ,THERAPEUTIC use of fibrinolytic agents - Abstract
Background An optimal antithrombotic strategy for patients aged 80 years or older with atrial fibrillation (AF) remains elusive. Objective Using a systematic review with traditional and network meta-analysis, we investigated outcomes in AF patients ≥80 years treated with different antithrombotic strategies. Methods We searched eligible randomised controlled trials (RCTs) and observational studies from MEDLINE, EMBASE, Cochrane Library and Web of Science databases from inception to 16 December 2021. Research comparing treatment outcomes of novel oral anticoagulants (NOACs), aspirin, vitamin K antagonists (VKAs) or no oral anticoagulant/placebo therapy in patients ≥80 years with AF were included. Outcomes were stroke or systemic embolism (SSE), major bleeding, all-cause mortality, intracranial bleeding (ICH) and gastrointestinal bleeding. Traditional and network meta-analyses were performed. Net clinical benefit integrating SSE and major bleeding was calculated. Results Fifty-three studies were identified for analysis. In the meta-analysis of RCTs, risk of SSE (risk ratio [RR]: 0.82; 95% confidence interval [CI]: 0.73–0.99) and ICH (RR: 0.38; 95% CI: 0.28–0.52) was significantly reduced when NOACs were compared with VKAs. Network meta-analysis of RCTs demonstrated that edoxaban (P -score: 0.8976) and apixaban (P -score: 0.8528) outperformed other antithrombotic therapies by showing a lower major bleeding risk and better net clinical benefit. Both traditional and network meta-analyses from RCTs combining with observational studies showed consistent results. Conclusions In patients aged 80 years or older with AF, NOACs have better outcomes than VKAs regarding efficacy and safety profiles. Edoxaban and apixaban may be preferred treatment options since they are safer than other antithrombotic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
93. Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban.
- Author
-
Chao, Tze-Fan, Chan, Yi-Hsin, Tsai, Pei-Chien, Lee, Hsin-Fu, Chang, Shang-Hung, Kuo, Chi-Tai, Lip, Gregory Y. H., Chen, Shih-Ann, and Yeh, Yung-Hsin
- Subjects
ATRIAL fibrillation ,RIVAROXABAN ,ORAL medication ,PARTIAL thromboplastin time ,PROTHROMBIN - Abstract
Background: Although direct oral anticoagulants (DOACs) for patients with atrial fibrillation (AF) are considered to be safe, over or under anticoagulation and increased bleeding or thromboembolic risk are still considered individually. We aimed to investigate whether there is an association between prothrombin time and international normalized ratio (PT-INR) or activated partial thromboplastin time (aPTT) ratio, and the risks of ischemic stroke/systemic embolism (IS/SE) and major bleeding among AF patients taking rivaroxaban or dabigatran. Methods: This multi-center cohort study in Taiwan included 3192 AF patients taking rivaroxaban and 958 patients taking dabigatran for stroke prevention where data about PT-INR and aPTT were available. Results: For patients treated with rivaroxaban, a higher INR level was not associated with a higher risk of major bleeding compared to an INR level < 1.1. The risk of IS/SE was lower for patients having an INR ≥ 1.5 compared to those with an INR < 1.1 (aHR:0.57; [95%CI: 0.37–0.87]; p = 0.01). On-label dosing of rivaroxaban and use of digoxin were independent factors associated with an INR ≥ 1.5 after taking rivaroxaban. For patients taking dabigatran, a higher aPTT ratio was not associated with a higher risk of major bleeding. The risk of IS/SE was lower for patients having an aPTT ratio of 1.1–1.2 and 1.3–1.4 than those with an aPTT ratio < 1.1. Conclusions: In AF patients, rivaroxaban with an INR ≥ 1.5 was associated with a lower risk of IS/SE. PT-INR or aPTT ratios were not associated with bleeding events for rivaroxaban or dabigatran. INR may help predict the outcome of AF patients who take rivaroxaban. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
94. Performance of stent thrombosis and bleeding risk scores in out-of-hospital cardiac arrest due to acute coronary syndromes.
- Author
-
Seret, Gabriel, Pham, Vincent, Laghlam, Driss, Diefenbronn, Marine, Brunet, Thibaud, Varenne, Olivier, Dumas, Florence, Cariou, Alain, and Picard, Fabien
- Abstract
• OHCA due to ACS patients are at high risk of bleeding and stent thrombosis (ST). • ST and bleeding risk scores have been developed for ACS but never tested in OHCA. • Bleeding and ST risk scores have poor performance in OHCA patients. • Specific bleeding and ST risk scores should be developed for such patients. Patients with out-of-hospital cardiac arrest (OHCA) due to acute coronary syndromes (ACS) who undergo percutaneous coronary intervention (PCI) are at high risk of bleeding and thrombosis. While predictive bleeding and stent thrombosis risk scores have been established, their performance in patients with OHCA has not been evaluated. All consecutive patients admitted for OHCA due to ACS who underwent PCI between January 2007 and December 2019 were included. The ACTION and CRUSADE bleeding risk scores and the Dangas score for early stent thrombosis risk were calculated for each patient. A C-statistic analysis was performed to assess the performance of these scores. Among 386 included patients, 82 patients (21.2%) experienced severe bleeding and 30 patients (7.8%) experienced stent thrombosis. The predictive performance of the ACTION and CRUSADE bleeding risk scores for major bleeding was poor, with areas under the curve (AUCs) of 0.596 and 0.548, respectively. Likewise, the predictive performance of the Dangas stent thrombosis risk score was poor (AUC 0.513). Using multivariable analysis, prolonged low-flow (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.00–1.05; P = 0.025), reduced haematocrit or fibrinogen at admission (OR 0.93, 95% CI 0.88–0.98; P = 0.010 and OR 0.61; 95% CI 0.41–0.89; P = 0.012, respectively) and the use of glycoprotein IIb/IIIa inhibitors (OR 2.10, 95% CI 1.18–3.73; P = 0.011) were independent risk factors for major bleeding. The classic bleeding and stent thrombosis risk scores have poor performance in a population of patients with ACS complicated by OHCA. Other predictive factors might be more pertinent to determine major bleeding and stent thrombosis risks in this specific population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
95. Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF.
- Author
-
Kodani, Eitaro, Tomita, Hirofumi, Nakai, Michikazu, Akao, Masaharu, Suzuki, Shinya, Hayashi, Kenshi, Sawano, Mitsuaki, Goya, Masahiko, Yamashita, Takeshi, Fukuda, Keiichi, Ogawa, Hisashi, Tsuda, Toyonobu, Isobe, Mitsuaki, Toyoda, Kazunori, Miyamoto, Yoshihiro, Miyata, Hiroaki, Okamura, Tomonori, Sasahara, Yusuke, and Okumura, Ken
- Subjects
BLOOD pressure ,ATRIAL fibrillation ,JAPANESE people ,ISCHEMIC stroke ,CARDIOVASCULAR disease related mortality - Abstract
Aims: This study aimed to investigate the impact of baseline blood pressure (BP) on adverse outcomes in patients with atrial fibrillation (AF), using a pooled analysis performed on data from J-RISK AF, a large-scale cohort of Japanese patients with AF. Methods and results: Of the 16 918 patients from five major AF registries including the J-RHYTHM Registry, Fushimi AF Registry, Shinken Database, Keio interhospital Cardiovascular Studies, and Hokuriku-Plus AF Registry, 15 019 non-valvular AF (NVAF) patients with baseline BP values (age, 70.0 ± 11.0 years; men, 69.1%) were analysed. Incidence rates of adverse events were evaluated between patients divided into baseline systolic BP quartiles or at 150 mmHg. During the follow-up period of 730 days, ischaemic stroke, major bleeding, all-cause death, and cardiovascular death occurred in 277, 319, 718, and 275 patients, respectively. Hazard ratios (HRs) for ischaemic stroke and major bleeding were comparable among the quartiles, whereas HRs for all-cause and cardiovascular deaths in the lowest quartile with systolic BP <114 mmHg were significantly higher [HR 1.43, 95% confidence interval (CI) 1.13–1.81; and HR 1.47, 95% CI 1.01–2.12, respectively] than in the third quartile, even after adjusting for known confounding factors. In patients with a systolic BP of ≥150 mmHg, adjusted HR for major bleeding was significantly higher than that of <150 mmHg (HR 1.64, 95% CI 1.12–2.40). Conclusion: In Japanese patients with NVAF, a baseline systolic BP <114 mmHg was significantly associated with higher all-cause and cardiovascular mortality. In contrast, a systolic BP ≥150 mmHg was an independent risk factor for major bleeding. Graphical abstract [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
96. Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
- Author
-
Parfrey, Shane, Abdelrahman, Amr, Blackman, Daniel, Blaxill, Jonathan M., Cunnington, Michael S., Greenwood, John P., Malkin, Christopher J., Mozid, Abdul M., Rossington, Jennifer A., Veerasamy, Murugapathy, Wassef, Nancy, Wheatcroft, Stephen B., and Bulluck, Heerajnarain
- Subjects
PERCUTANEOUS coronary intervention ,PLATELET aggregation inhibitors ,RANDOMIZED controlled trials ,DRUG-eluting stents ,MYOCARDIAL infarction ,MORTALITY - Abstract
Very short duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has recently attracted a lot of attention with the introduction of newer generations stents. This is appealing, especially in patients at high bleeding risk. However, none of the trials were powered for the individual ischemic and bleeding endpoints. All randomised controlled trials (RCTs) investigating one-month versus routine duration of DAPT in patients undergoing PCI and reporting outcomes from the time of cessation of DAPT (1 month) to 1 year were eligible for inclusion in the meta-analysis. The pooled risk ratios (RR) with their 95% confidence interval (CI) were calculated with the random-effects model using the Mantel-Haenszel method. Four RCTs involving 26,576 patients were included in this meta-analysis. Cessation of DAPT after 1 month was associated with significantly less major bleeding [RR 0.70, 95%CI (0.51-0.95), P = 0.02, heterogeneity (I2) = 42%]. There was no statistically significant difference in all-cause mortality [RR 0.84 (95%CI 0.69-1.03), P = 0.10, I2 = 0%] and stroke [RR 0.71 (95%CI 0.45-1.13), P = 0.15, I2 = 42%] when compared to routine duration of DAPT. There was also no difference in myocardial infarction (MI) [RR 1.12 (95%CI 0.91-1.39), P = 0.28, I2 = 0%], and definite or probable stent thrombosis [RR 1.49 (95%CI 0.92-2.41), P = 0.11, I2 = 0%] with cessation of DAPT after 1 month. Cessation of DAPT 1 month after PCI was associated with significantly less major bleeding, but there was no difference in the rate of all-cause mortality, stroke, MI and stent thrombosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
97. Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.
- Author
-
Berger, Jeffrey S., Laliberté, François, Kharat, Akshay, Lejeune, Dominique, Moore, Kenneth Todd, Jung, Young, Lefebvre, Patrick, and Ashton, Veronica
- Abstract
Prior observational studies suggest rivaroxaban is safe and effective among patients with morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are more limited in the broader population of VTE patients with obesity. This study assessed VTE recurrence, major bleeding, healthcare resource utilization, and healthcare costs among VTE patients with obesity who received rivaroxaban versus warfarin. VTE patients with obesity who initiated rivaroxaban or warfarin after a first VTE (index date) were identified from the IQVIA PharMetrics® Plus database (01/02/2011–09/30/2019). The follow-up period spanned from the index date until health plan disenrollment, end of data availability, cancer diagnosis/treatment, end of the 12 month post-index period, or (for the analysis of major bleeding) anticoagulant discontinuation or switch. Patient characteristics were balanced using inverse probability of treatment weighting. The weighted rivaroxaban (N = 8666) and warfarin cohorts (N = 5946) were well balanced (mean age = 51 years, females = 52%). Over a 9.6 months mean observation period, rivaroxaban users had a significantly lower risk of VTE recurrence [7.0% vs. 8.2%, HR(95% CI) = 0.85(0.75;0.97)] and a similar risk of major bleeding [4.1% vs. 3.6%, HR(95% CI) = 1.11(0.89;1.37)] relative to warfarin users at 12 months. Relative to warfarin users, rivaroxaban users had significantly fewer all-cause outpatient visits [RR(95% CI) = 0.71(0.70;0.74)]. The higher pharmacy costs incurred by rivaroxaban recipients (cost difference = $1252) were offset by lower medical costs (cost difference = − $2515, all p < 0.05) compared with warfarin recipients. Our findings suggest that rivaroxaban is safe and effective versus warfarin, and associated with lower medical costs among VTE patients with obesity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
98. CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
- Author
-
Haoyi Yao, Kaijie Qin, Yun Liu, Yi Yang, Jiaxi Zhu, Anqing Chen, Zhe Wang, Xiaofeng Ye, Mi Zhou, Haiqing Li, Jiapei Qiu, Qiang Zhao, and Yunpeng Zhu
- Subjects
dual antiplatelet therapy (DAPT) ,CYP2C19 genotype ,platelet aggregation test (PAgT) ,off-pump coronary artery bypass grafting (OPCAB) ,major adverse cardiovascular events (MACE) ,major bleeding ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundDual antiplatelet therapy (DAPT) is recommended in patients undergoing off-pump coronary artery bypass graft surgery (OPCAB). Clopidogrel is less effective among patients with loss-of-function (LoF) of CYP2C19 alleles, while ticagrelor has direct effects on P2Y12 receptor. Whether a CYP2C19 genotype plus platelet aggregation test (PAgT)-guided DAPT after CABG could improve clinical outcomes remain uncertain.Materials and methodsFrom August 2019 to December 2020, 1,134 consecutive patients who underwent OPCAB received DAPT for 1 year after surgery in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. According to the actual treatment they received in real-world, 382 (33.7%) of them received a traditional DAPT: aspirin 100 mg qd + clopidogrel 75 mg qd, no matter the CYP2C19 genotype and response in platelet aggregation test (PAgT). The other 752 (66.3%) patients received an individual DAPT based on CYP2C19 genotype and PAgT: aspirin 100 mg qd + clopidogrel 75 mg qd if CYP2C19 was extensive metabolizer, or moderate metabolizer but normal response in PAgT; aspirin 100 mg qd + ticagrelor 90 mg bid if CYP2C19 was poor metabolizer, or moderate metabolizer but no or low response in PAgT. One-year follow-up was achieved for all patients. The primary outcome was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke. The safety outcome was thrombolysis in myocardial infarction (TIMI) criteria major bleeding.ResultsCompared with the traditional DAPT group, the risk of MACE in the individual DAPT group was significantly lower (5.5 vs. 9.2%, HR 0.583; 95% CI, 0.371–0.915; P = 0.019), mainly due to the decreased risk of MI (1.7 vs. 4.2%, HR 0.407; 95% CI, 0.196–0.846; P = 0.016). The risk of TIMI major bleeding events was similar between the two groups (5.3 vs. 6.0%, RR 0.883; 95% CI, 0.537–1.453; P = 0.626).ConclusionFor patients who underwent OPCAB, individual DAPT (CYP2C19 genotype plus PAgT-guided strategy) was associated with a lower risk of MACE and a similar risk of major bleeding.
- Published
- 2022
- Full Text
- View/download PDF
99. Performance of the ABC-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: A real-world study
- Author
-
Yu-Feng Wang, Chao Jiang, Liu He, Cun-Ying Pu, Xin Du, Cai-Hua Sang, De-Yong Long, Ri-Bo Tang, Jian-Zeng Dong, and Chang-Sheng Ma
- Subjects
atrial fibrillation ,ABC-bleeding risk score ,HAS-BLED score ,major bleeding ,anticoagulation ,real-world study ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
ObjectiveTo evaluate performance of the ABC (Age, Biomarkers, Clinical history)-bleeding risk score in estimating major bleeding risk in Chinese patients with atrial fibrillation (AF) on oral anticoagulation (OAC) therapy in real-world practice.MethodsData were collected from the Chinese Atrial Fibrillation Registry study (CAFR). Patients were stratified into low-, medium-, and high-risk groups based on ABC-bleeding risk score with 1-year major bleeding risk ( 2%) and modified HAS-BLED score (≤1, 2, and > 2 points). Cox proportional-hazards (Cox-PH) models were used to determine the association of major bleeding incidence with bleeding scores. Harrell’s C-index of the two scores were compared. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) at 1 year were employed to evaluate the reclassification capacity. The calibration curve was plotted to compare the predicted major bleeding risk using ABC-bleeding risk score with the observed annualized event rate. The decision analysis curves (DCA) were performed to show the clinical utilization of two scores in identifying major bleeding events.ResultsThe study included 2,892 AF patients on OAC therapy. After the follow-up of 3.0 years, 48 patients had major bleeding events; the incidence of a bleeding event in the low-, medium-, and high-risk groups according to ABC-bleeding risk score was 0.31% (reference group, HR = 1.00),0.51% (HR = 1.83, 95%CI: 0.91–3.69, P = 0.09), and 1.49% (HR = 4.92, 95%CI: 2.34–10.30, P < 0.001), respectively. Major bleeding incidence had an independent association with growth differentiation factor 15 (GDF-15) level (HR = 2.16, 95%CI: 1.27–3.68, P = 0.005) after adjusting components of the HAS-BLED score and cTnT-hs level. The ABC-bleeding score showed a Harrell’s C-index of 0.67 (95%CI: 0.60–0.75) in estimating major bleeding risk, which was non-significant compared to the modified HAS-BLED score (0.67 vs. 0.63; P = 0.38). NRI and IDI also revealed comparable reclassification capacity of ABC-bleeding risk score compared with HAS-BLED score (14.6%, 95%CI: −10.2%, 39.4%, P = 0.25; 0.2%, 95%CI −0.1 to 0.9%, P = 0.64). Cross-tabulation of the two scores showed that the ABC-bleeding score outperformed the HAS-BLED score in identifying patients with a high risk of major bleeding. The calibration curve showed that the ABC-bleeding risk score overestimated the observed major bleeding risk. DCA did not show any difference in net benefit when using either of the scores.ConclusionThis study verified the value of the ABC-bleeding risk score in assessing major bleeding risk in Chinese patients with AF on OAC therapy in real-world practice. Despite the overestimation of major bleeding risk, ABC-bleeding score performed better in stratifying patients with a high risk than the modified HAS-BLED score. Combining the two scores could be a clinically practical strategy for precisely stratifying AF patients, especially those at a high risk of major bleeding, and further supporting the optimization of OAC treatment.
- Published
- 2022
- Full Text
- View/download PDF
100. In-hospital major bleeding in patients with acute coronary syndrome medically treated with dual anti-platelet therapy: Associated factors and impact on mortality
- Author
-
Yihong Sun, Lin Feng, Xian Li, Zhe Wang, Runlin Gao, and Yangfeng Wu
- Subjects
acute coronary syndrome ,risk factors ,major bleeding ,mortality ,antithrombotic therapy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
ObjectiveMajor bleeding is associated with poor hospital prognosis in patients with acute coronary syndrome (ACS). Despite its clinical importance, there are limited studies on the incidence and risk factors for major bleeding in ACS patients with dual anti-platelet therapy (DAPT) without access to revascularization.MethodsWe analyzed data from 19,186 patients on DAPT after ACS with no access to revascularization from Clinical Pathway for Acute Coronary Syndrome in China Phase 3 (CPACS-3) cohort, which was conducted from 2011 to 2014. Major bleeding included intracranial hemorrhage, clinically significant bleeding, or bleeding requiring blood transfusion. Factors associated with in-hospital major bleeding were assessed using Poisson regressions with generalized estimating equations to account for the clustering effect.ResultsA total of 75 (0.39%) patients experienced major bleeding during hospitalization. Among subtypes of ACS, 0.65% of patients with STEMI, 0.33% with NSTEMI, and 0.13% with unstable angina had in-hospital major bleeding (p < 0.001). The patients who experienced major bleeding had a longer length of stay (median 12 vs. 9 days, p = 0.011) and a higher all-cause in-hospital death rate (22.7 vs. 3.7%, p < 0.001). Multivariable analysis showed advancing age (RR = 1.52 for every 10 years increase, 95% CI: 1.13, 2.05), impaired renal function (RR = 1.79, 95% CI: 1.10, 2.92), use of fibrinolytic drugs (RR = 2.93, 95% CI: 1.55, 5.56), and severe diseases other than cardiovascular and renal diseases (RR = 5.56, 95% CI: 1.10, 28.07) were associated with increased risk of major bleeding, whereas using renin–angiotensin system inhibitors (RR = 0.54, 95% CI: 0.36, 0.81) was associated with decreased risk of major bleeding. These independent factors together showed good predictive accuracy with an AUC of 0.788 (95% CI: 0.734, 0.841).ConclusionAmong ACS patients on DAPT, advancing age, impaired renal function, thrombolytic treatment, and severe comorbidities were independently associated with a higher risk of in-hospital major bleeding.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.